Articles & Issues

Alert me when new Journal Issues are available via Email Alert or RSS Feed

Decade: 2010-2019

Year: 2011

Issue: Vol 12 | No. 3 | November 2011 | Pages 265-288

Novel strategies for raising HDL-C: Pitavastatin in clinical practice

This supplement has been produced with the support of an unrestricted educational grant from Kowa Pharmaceutical Europe Co. Ltd.

Search Within This Issue

6 Articles:

Article Title	Author(s)	Pages
Editorial Board PDF (46 KB)		iii
Introduction Preview Abstract PDF (61 KB) Abstract: Lowering low-density lipoprotein-cholesterol (LDL-C) levels using statins can significantly reduce cardiovascular (CV) risk in patients with dyslipidemia. However, the risk of major vascular...	Philip Barter	265-266
HDL-C: Role as a risk modifier Preview Abstract Abstract + References PDF (134 KB) Abstract: Evidence that low-density lipoprotein-cholesterol (LDL-C) causes cardiovascular disease (CVD) is overwhelming. It has also been proven beyond all doubt that lowering the level of LDL-C using...	Philip Barter	267-270
Pitavastatin: An overview Preview Abstract Abstract + References PDF (212 KB) Abstract: Compared to other statins, pitavastatin is a highly potent 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitor and an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-...	Yasushi Saito	271-276
Pitavastatin: Novel effects on lipid parameters Preview Abstract Abstract + References PDF (174 KB) Abstract: Atherogenic dyslipidemia is characterised by high levels of triglycerides, low levels of high-density lipoprotein-cholesterol (HDL-C), and moderate to marked elevations in low-density lipopr...	M. John Chapman	277-284
Pitavastatin: Clinical effects from the LIVES Study Preview Abstract Abstract + References PDF (87 KB) Abstract: Although clinical trials provide useful information on drug safety and efficacy, results do not always reflect those observed in the real world. The Japanese long-term prospective post-marke...	Tamio Teramoto	285-288